NCT07422805

Circulating Tumor DNA in Melanoma Patients

Significance of Detection and Quantification of Circulating Tumor DNA in the Treatment of Melanoma Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 113 (actual)
• Sponsor: Institute of Oncology Ljubljana · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this prospective observational study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study will evaluate the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.

Detailed description

This is a prospective observational cohort study designed to evaluate the clinical significance of circulating tumor DNA (ctDNA) detection and quantification in patients with melanoma. The main purpose of the study is to determine whether the presence and quantity of ctDNA may represent a predictive biomarker for melanoma recurrence or disease progression. The study will assess the relationship between ctDNA levels and established clinical and histopathological prognostic factors. ctDNA detection and quantification will be performed and correlated with relevant patient and tumor characteristics. The study will also evaluate whether ctDNA measurement can contribute to improved monitoring of melanoma patients and prediction of treatment outcomes. The study is conducted at the Institute of Oncology Ljubljana as a prospective cohort study and includes melanoma patients who are followed over time. The collected data will be analyzed to determine associations between ctDNA presence/quantity and recurrence or progression of melanoma.

Conditions

• Melanoma
• Skin Cancer

Interventions

Type	Name	Description
OTHER	Blood Sampling for ctDNA Analysis	Collection of peripheral blood samples for detection and quantification of circulating tumor DNA (ctDNA) and evaluation of its association with clinical outcomes in melanoma patients.

Timeline

• Start date: 2021-11-01
• Primary completion: 2023-11-30
• Completion: 2023-11-30
• First posted: 2026-02-20
• Last updated: 2026-02-24

Locations

1 site across 1 country: Slovenia